No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
VTGN250117C1000
- 0.00
- 0.000.00%
15min DelayClose Dec 24 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover232.35%IV-60.78%PremiumJan 17, 2025Expiry Date1.55Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9699Delta0.0451Gamma1.62Leverage Ratio-0.0022Theta0.0006Rho1.57Eff Leverage0.0004Vega
Intraday
- 5D
- Daily
No Data
News
VistaGen Therapeutics Advances Neurocircuitry Treatments
Stifel Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Vistagen to Present at the Stifel 2024 Healthcare Conference
Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript Summary
VistaGen Therapeutics' Promising Clinical Progress and Strong Financial Position Justify Buy Rating
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12